Get the Stockscreener App
10.04
0.00%
0.00
Immatics N V stock is traded at $10.04, with a volume of 238.21K.
It is up +0.00% in the last 24 hours and down -5.90% over the past month.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
See More
Previous Close:
$10.04
Open:
$10.12
24h Volume:
238.21K
Relative Volume:
0.31
Market Cap:
$1.35B
Revenue:
$58.49M
Net Income/Loss:
$-105.04M
P/E Ratio:
-7.7249
EPS:
-1.2997
Net Cash Flow:
$-13.78M
1W Performance:
-1.38%
1M Performance:
-5.90%
6M Performance:
+63.52%
1Y Performance:
+35.49%
1-Day Range:
$9.88
$10.22
1-Week Range:
$9.75
$10.50
52-Week Range:
$3.30
$12.41
Immatics N V Stock (IMTX) Company Profile
Compare IMTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMTX
Immatics N V
|
10.04 | 1.35B | 58.49M | -105.04M | -13.78M | -1.2997 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immatics N V Stock (IMTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | Guggenheim | Buy |
| May-28-25 | Initiated | Deutsche Bank | Buy |
| Oct-07-24 | Initiated | Piper Sandler | Overweight |
| Nov-02-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Mar-24-23 | Initiated | Bryan Garnier | Buy |
| Nov-20-20 | Initiated | BofA Securities | Buy |
| Sep-22-20 | Initiated | Goldman | Buy |
| Jul-27-20 | Initiated | SVB Leerink | Outperform |
| Jul-24-20 | Initiated | Jefferies | Buy |
View All
Immatics N V Stock (IMTX) Latest News
Immatics (IMTX) Updates on Promising IMA203CD8 Cell Therapy Tria - GuruFocus
Immatics presents IMA203CD8 PRAME cell therapy data at ESMO-IO Congress - TipRanks
Immatics Reveals Promising Results from IMA203CD8 Phase 1a Trial - TipRanks
Immatics (NASDAQ: IMTX) reports 46% ORR for IMA203CD8 in Phase 1a PRAME solid tumors - Stock Titan
Is Immatics NV a good long term investmentMorning Star Patterns & Breakthrough Stock Performance - earlytimes.in
A look into Immatics N.V (IMTX)’s deeper side - setenews.com
Immatics Completes $116.5 Million Share Offering to Boost R&D - TipRanks
Immatics completes $116.5 million share offering to boost R&D - MSN
Immatics announces offering of 12.5M ordinary shares - MSN
How Investors Are Reacting To Immatics (IMTX) $125 Million Follow-On Equity Offering - simplywall.st
Finance Watch: Biotech Investors Take FDA Turmoil In Stride - Citeline News & Insights
Immatics (NASDAQ:IMTX) Trading Up 8.9%Time to Buy? - MarketBeat
Immatics Down Nearly 15%, on Pace for Largest Percent Decrease Since October 2024 -- Data Talk - 富途牛牛
Immatics announces $125 million underwritten offering - marketscreener.com
Immatics Announces $125 Million Underwritten Offering - TradingView
Perhaps timely catching Immatics N.V (IMTX) would be a good idea - Setenews
Immatics Plans $125 Million Stock Offering - marketscreener.com
Immatics (Nasdaq: IMTX) files share offering, reports 46% ORR and 9.2‑month mDOR - Stock Titan
Immatics N.V. Announces Agreement to Sell 12.5 Million Ordinary Shares in Underwritten Offering - Quiver Quantitative
Immatics (NASDAQ: IMTX) to sell 12,500,000 shares at $10.00 in underwritten offering - Stock Titan
Revenues Not Telling The Story For Immatics N.V. (NASDAQ:IMTX) After Shares Rise 28% - simplywall.st
Immatics N.V.'s (NASDAQ:IMTX) 28% Price Boost Is Out Of Tune With Revenues - 富途牛牛
Immatics (NASDAQ:IMTX) Sets New 12-Month HighHere's What Happened - MarketBeat
How Immatics N.V. (4A3) stock compares with tech leaders2025 Bull vs Bear & Smart Allocation Stock Reports - Newser
Price-Driven Insight from (IMTX) for Rule-Based Strategy - news.stocktradersdaily.com
Is Immatics N.V. (4A3) stock included in top ETFsGold Moves & Short-Term Trading Alerts - Newser
Why pension funds invest in Immatics N.V. (4A3) stockWeekly Profit Recap & Weekly Watchlist of Top Performers - Newser
What dividend safety rating applies to Immatics N.V. (4A3) stockJuly 2025 WrapUp & Community Trade Idea Sharing Platform - Newser
Why Immatics N.V. (4A3) stock could rally stronglyJuly 2025 Recap & AI Enhanced Trading Alerts - Newser
Immatics (IMTX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Why Immatics N.V. Equity Warrant stock could outperform in 2025Weekly Earnings Recap & AI Enhanced Trading Signals - Newser
Is Immatics N.V. (4A3) stock a buy before new product rolloutIPO Watch & Free Fast Entry Momentum Trade Alerts - Newser
Why Immatics N.V. stock is considered a top pick2025 Risk Factors & Precise Buy Zone Identification - BỘ NỘI VỤ
Why Immatics N.V. stock is rated strong buy2025 Growth vs Value & High Win Rate Trade Tips - BỘ NỘI VỤ
Immatics Reports Q3 2025 Financial Results and Business Update - MSN
FY2025 EPS Estimates for Immatics Lowered by Chardan Capital - MarketBeat
How Rising Losses in the Latest Results Will Impact Immatics (IMTX) Investors - simplywall.st
Is Immatics N.V. (4A3) stock a top dividend aristocrat candidateJuly 2025 Selloffs & Weekly Chart Analysis and Guides - BỘ NỘI VỤ
Immatics N.V. Reports Q3 2025 Financial Results and Progress - MSN
How sustainable is Immatics N.V. stock dividend payoutGDP Growth & Weekly High Momentum Picks - BỘ NỘI VỤ
Views of Wall Street’s Leading Experts on Immatics N.V - Setenews
Chardan Capital Reaffirms Buy Rating for Immatics (NASDAQ:IMTX) - MarketBeat
Chardan Capital Maintains Immatics N.V. (IMTX) Buy Recommendation - Nasdaq
IMTX: Chardan Capital Maintains Buy Rating with $25 Target | IMT - GuruFocus
(IMTX) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Immatics FY2025 EPS Estimate Boosted by Cantor Fitzgerald - MarketBeat
Immatics FY2025 EPS Estimate Lifted by Cantor Fitzgerald - Defense World
FY2025 EPS Estimates for Immatics Boosted by Leerink Partnrs - MarketBeat
Will Immatics N.V. (4A3) stock return to pre crash levelsIPO Watch & Risk Controlled Swing Alerts - newser.com
Heatmap analysis for Immatics N.V. and competitorsJuly 2025 Volume & AI Driven Price Forecasts - newser.com
What macro factors could drive Immatics N.V. (4A3) stock higherBear Alert & Low Drawdown Momentum Ideas - newser.com
Immatics N V Stock (IMTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):